Seattle Genetics, Inc. (NASDAQ:SGEN) insider Vaughn B. Himes sold 5,000 shares of the company’s stock in a transaction on Friday, November 30th. The stock was sold at an average price of $62.14, for a total transaction of $310,700.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Vaughn B. Himes also recently made the following trade(s):
- On Friday, September 7th, Vaughn B. Himes sold 5,000 shares of Seattle Genetics stock. The stock was sold at an average price of $76.99, for a total transaction of $384,950.00.
SGEN opened at $62.04 on Friday. Seattle Genetics, Inc. has a 52 week low of $47.75 and a 52 week high of $84.37. The stock has a market cap of $9.78 billion, a price-to-earnings ratio of -70.31 and a beta of 2.20.
Seattle Genetics (NASDAQ:SGEN) last released its quarterly earnings data on Thursday, October 25th. The biotechnology company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.15). Seattle Genetics had a negative net margin of 26.58% and a negative return on equity of 19.13%. The company had revenue of $169.42 million for the quarter, compared to the consensus estimate of $164.75 million. On average, equities research analysts forecast that Seattle Genetics, Inc. will post -1.44 earnings per share for the current fiscal year.
SGEN has been the subject of several recent analyst reports. Zacks Investment Research raised shares of Seattle Genetics from a “hold” rating to a “buy” rating and set a $85.00 target price for the company in a report on Thursday, August 23rd. BidaskClub raised shares of Seattle Genetics from a “hold” rating to a “buy” rating in a report on Wednesday, August 15th. Guggenheim initiated coverage on shares of Seattle Genetics in a report on Monday, September 17th. They issued a “buy” rating for the company. JPMorgan Chase & Co. reaffirmed a “buy” rating and issued a $85.00 target price on shares of Seattle Genetics in a report on Wednesday, September 26th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $98.00 target price on shares of Seattle Genetics in a report on Friday, October 26th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company’s stock. Seattle Genetics currently has a consensus rating of “Buy” and an average target price of $77.77.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Baker BROS. Advisors LP boosted its holdings in shares of Seattle Genetics by 3.0% during the 2nd quarter. Baker BROS. Advisors LP now owns 51,046,060 shares of the biotechnology company’s stock valued at $3,388,948,000 after purchasing an additional 1,470,651 shares during the last quarter. Benjamin F. Edwards & Company Inc. raised its position in shares of Seattle Genetics by 251.4% during the 3rd quarter. Benjamin F. Edwards & Company Inc. now owns 8,610 shares of the biotechnology company’s stock valued at $664,000 after buying an additional 6,160 shares in the last quarter. Toronto Dominion Bank raised its position in shares of Seattle Genetics by 27.3% during the 3rd quarter. Toronto Dominion Bank now owns 26,753 shares of the biotechnology company’s stock valued at $2,063,000 after buying an additional 5,734 shares in the last quarter. Paloma Partners Management Co raised its position in shares of Seattle Genetics by 69.0% during the 2nd quarter. Paloma Partners Management Co now owns 26,018 shares of the biotechnology company’s stock valued at $1,728,000 after buying an additional 10,619 shares in the last quarter. Finally, Cookson Peirce & Co. Inc. purchased a new stake in shares of Seattle Genetics during the 3rd quarter valued at about $715,000.
COPYRIGHT VIOLATION WARNING: “Seattle Genetics, Inc. (SGEN) Insider Sells $310,700.00 in Stock” was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this report on another domain, it was illegally copied and republished in violation of U.S. & international trademark & copyright law. The legal version of this report can be read at https://www.dispatchtribunal.com/2018/12/07/seattle-genetics-inc-sgen-insider-sells-310700-00-in-stock.html.
Seattle Genetics Company Profile
Seattle Genetics, Inc, a biotechnology company, focuses on the development and commercialization of targeted therapies for the treatment of cancer worldwide. It markets ADCETRIS, an antibody-drug conjugate for the treatment of relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma.
Further Reading: What is a Candlestick Chart?
Receive News & Ratings for Seattle Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seattle Genetics and related companies with MarketBeat.com's FREE daily email newsletter.